Welcome to our dedicated page for Assertio Holdings news (Ticker: ASRT), a resource for investors and traders seeking the latest updates and insights on Assertio Holdings stock.
Assertio Holdings Inc (ASRT) is a pharmaceutical innovator specializing in neurology and specialty medicines, offering investors comprehensive news coverage through this dedicated hub. Access real-time updates on FDA-approved therapies, strategic partnerships, and financial developments shaping this dynamic healthcare company.
This resource provides verified press releases and analysis-free announcements covering earnings reports, product launches, and regulatory milestones. Track ASRT's progress in neurology treatments and oncology initiatives like Rolvedon through primary source documentation.
Key updates include acquisition activities, licensing agreements, and commercial strategy developments. Investors gain direct access to the company's official communications regarding market expansion, payor contracting progress, and distribution network enhancements.
Bookmark this page for unfiltered access to Assertio's latest developments in specialty pharmaceuticals. Monitor their focused approach to neurological care and orphan drug commercialization through timely, regulation-compliant disclosures.
Assertio Holdings, Inc. will present at the Citizens JMP Life Sciences Conference in New York City on May 13, 2024. Ajay Patel, Chief Financial Officer, will lead the presentation at 12:00 pm Eastern Time. Investors can request meetings with the Company through JMP representatives or contact Assertio investor relations. Presentation information will be available on the event day at https://investor.assertiotx.com. To listen to the webcast, connect to the website link 15 minutes before the live webcast.
Assertio Holdings, Inc. reported strong first-quarter financial results, with net product sales of $31.9 million. Rolvedon product sales increased, while Indocin sales decreased due to generic competition. The company's gross margin was 65%, SG&A expenses decreased, and adjusted EBITDA improved. Assertio generated $7.5 million in cash flow, ending the quarter with $80.7 million in cash and cash equivalents. The company reiterated its 2024 financial guidance of $110-125 million in net product sales and $20-30 million in adjusted EBITDA.
FAQ
What is the current stock price of Assertio Holdings (ASRT)?
What is the market cap of Assertio Holdings (ASRT)?
